Loading clinical trials...
Loading clinical trials...
Inhibition of Delta-protein Kinase C for the Reduction of Infarct Size in Acute Myocardial Infarction
The purpose of this study is to determine whether KAI-9803 is safe and effective in reducing infarct size in subjects with ST elevation myocardial infarction (heart attack) undergoing a percutaneous coronary intervention (PCI). A select number of sites will also participate in a substudy where eligible patients will undergo an additional procedure;cardiac magnetic resonance imaging.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Huntsville, Alabama, United States
Escondido, California, United States
Torrance, California, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Downers Grove, Illinois, United States
Lombard, Illinois, United States
Peoria, Illinois, United States
Valparaiso, Indiana, United States
Omaha, Nebraska, United States
Start Date
November 1, 2008
Primary Completion Date
July 1, 2010
Completion Date
May 1, 2011
Last Updated
September 2, 2011
1,180
ACTUAL participants
KAI-9803
DRUG
Lead Sponsor
KAI Pharmaceuticals
Collaborators
NCT06744322
NCT05198791
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06909773